Welcome to AiCuris: The Powerhouse for Anti-Infectives

AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.




Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.

Meet us at the BIO-EUROPE®



10 years of AiCuris!
mini-symposium / press conference / company presentation

We would be delighted to welcome you at our mini-symposium and press conference on Tuesday 8th November (11:00 am – 12:00 noon, BIO.NRW booth no. 100) to discuss “Challenges and breakthroughs of anti-infective therapies” with you. 

 Read more ...

Letermovir: positive Phase 3 data


AiCuris’ anti HCMV drug Letermovir meets Primary Endpoint

AiCuris’ licensee Merck reports that Letermovir, a prophylactic treatment against HCMV in bone marrow transplant patients, meets Primary Endpoint in Pivotal Phase III Study. 

 Read more ...

AiCuris in Going Public Case Studies


A Decade of Passion for Resistance-Breaking Anti-Infectives

When AiCuris was founded 10 years ago in Wuppertal, as a spin-out from Bayer Pharma, anti-infectives and the problem of increasing bacterial and viral resistance to common treatments.    

 Read more ...